The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity
about
Statistical considerations for stopping systemic lupus erythematosus clinical trials earlierUse of biologics in SLE: a review of the evidence from a clinical perspectiveIdentification of Candidate Predictors of Lupus FlareMeasuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical researchApproaches for estimating minimal clinically important differences in systemic lupus erythematosusProgress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activityTocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage.The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.Basophils and the T helper 2 environment can promote the development of lupus nephritis.Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohortMinimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus.Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosusAnti-C1q antibodies as a follow-up marker in SLE patientsSystemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.New treatment options for lupus - a focus on belimumab.Cause-effect relations between 55 kD soluble TNF receptor concentrations and specific and unspecific symptoms in a patient with mild SLE disease activity: an exploratory time series analysis study.Complete remission of human parvovirus b19 associated symptoms by loxoprofen in patients with atopic predispositions.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort studyImproved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1.Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials.The Paediatric Rheumatology International Trials Organization (PRINTO).Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies.Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus.A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosusNovel evidence-based systemic lupus erythematosus responder index.Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection.A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus.Measuring outcomes in systemic lupus erythematosus clinical trials.B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.Top 10 things to know about lupus activity measures.Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosusMycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus.Cardiovascular training vs. resistance training for improving quality of life and physical function in patients with systemic lupus erythematosus: a randomized controlled trial.Physicochemical and immunological studies on mitochondrial DNA modified by peroxynitrite: implications of neo-epitopes of mitochondrial DNA in the etiopathogenesis of systemic lupus erythematosus.Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs.A comparison of patients' and physicians' assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire.PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis
P2860
Q26774880-3DA5C8A8-C4B4-4D4D-AF16-4B16B82EFA07Q26783652-2163D5CB-B7E9-4CF6-ABD5-854D641C5E8DQ26795372-D4B69EB1-16A5-4BAF-B655-A5419A69F421Q26799223-DB3FE2C4-71BB-40CA-8B94-9BD94752E50CQ27021623-E1E131A0-F46C-41E1-8A8F-011556A78946Q28079267-9548C722-37C5-41D6-82F9-374E5163C324Q33527462-02C4AFD4-E2C2-43B1-9357-3487B5E05B79Q33635868-F90B7B35-DADF-471C-94A8-2327078D5D03Q33796222-73F5676B-7EA1-412C-8674-43DC6DD56B73Q34018381-0693E4B5-869A-4A6C-B3DD-C64965313283Q34044918-039C618D-1A65-48D9-810D-C5F5658A3853Q34046983-12351097-69C8-4F98-9488-9D84E6751D91Q35102127-2BFC7CF8-8CCC-4F7A-8628-C81A142BF923Q35448756-5F8699AC-6AE6-4908-990F-6D2F5546038BQ35637820-2C101C6C-3B7C-403E-89A8-6E69A3C615F8Q35752030-3E2EC1DF-4ECD-413B-966A-7E2403B35A03Q35782408-CA53C87E-C5CB-4DC1-9FAD-CDA9CD6F6D6DQ35947888-886A3A60-DAFC-4F77-8838-C98842467043Q35993027-4DE2AA78-3D3B-4B75-8445-5A31DD6DCF4AQ36321563-1AD3CD0C-EC99-422F-9151-166A49216AD4Q36477458-E3F73D2B-27EE-4C45-AAC8-F10FFA618AA1Q36896792-519CB52A-C141-432C-8CF8-D5723C01D219Q36915684-34E23D05-68AA-4B9A-B148-284611566A7EQ37037746-545FED82-596B-4EE8-B687-468B51069B72Q37101364-A78E8DA8-648A-4274-BBDA-8A884A2B4DB3Q37277281-6EABEB6B-15AA-42CA-AA5E-63BE0EBFEE57Q37356378-727E9773-362F-401A-8482-11100B256F5EQ37464019-89DEADC4-1AA1-4331-9C37-AC030BBA50A1Q37599137-0A072513-2E6C-4331-A183-4E00CDB16C2EQ37914899-C8FBBA6D-3E0C-4965-AB99-77265AC74E00Q38086135-D36BCFE0-F8F2-4AF2-8CB3-97780B3F73E2Q38100735-4FE03EFA-B254-4110-A346-21449DDC301AQ42282494-06130733-FBEB-415A-AEF2-28F719A121FFQ42638034-A4676BE9-0833-417A-A5B6-9B03757AB031Q46374758-433A30E1-5489-467E-8469-56381711BD40Q47922977-2A51C53E-0714-4A02-8619-2AC7A1EA3630Q47938979-1C615068-43D7-4972-92FB-098AE694DB7AQ49789514-9BC7C07C-15B4-4F35-8CBF-2F3B25370205Q54714606-12668292-B789-4A67-8B06-B6AE53FB72D6Q56942132-FA665BF0-0949-4471-BF6B-050EA29905B1
P2860
The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2004
@uk
name
The American College of Rheuma ...... es of overall disease activity
@en
The American College of Rheuma ...... es of overall disease activity
@nl
type
label
The American College of Rheuma ...... es of overall disease activity
@en
The American College of Rheuma ...... es of overall disease activity
@nl
prefLabel
The American College of Rheuma ...... es of overall disease activity
@en
The American College of Rheuma ...... es of overall disease activity
@nl
P356
P1476
The American College of Rheuma ...... es of overall disease activity
@en
P304
P356
10.1002/ART.20628
P577
2004-11-01T00:00:00Z